Adaptive Biotechnologies (ADPT) Price & Analysis

Compare

949 Followers

ADPT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.98 - $13.37

Previous CloseN/A

Volume480.81K

Average Volume (3M)1.95M

Market Cap

$1.97B

Enterprise Value$1.79B

Total Cash (Recent Filing)$197.87M

Total Debt (Recent Filing)$84.37M

Price to Earnings (P/E)―

Beta1.78

Next Earnings

Oct 30, 2025

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding152,273,910

10 Day Avg. Volume2,753,311

30 Day Avg. Volume1,947,719

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.91

Enterprise Value/Revenue8.73

Enterprise Value/Gross Profit13.22

Enterprise Value/Ebitda-18.17

Forecast

1Y Price Target

$13.75

Price Target Upside5.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Financial PerformanceAdaptive Biotechnologies reported revenues above consensus, driven by strong MRD revenues and clonoSEQ volume growth.

ProfitabilityThe company achieved positive adjusted EBITDA in the MRD business ahead of schedule, indicating better-than-expected financial performance.

Bears Say

Market CompetitionShares currently trade at 6 times 2025 MRD revenue, and if it is successful in achieving profitability while still growing the MRD business at approximately 25%, there is material upside to shares.

ValuationThe valuation has now aligned with comparable companies, suggesting a possible period of consolidation.

Adaptive Biotechnologies News

Adaptive Biotechnologies price target raised to $15 from $13 at Piper Sandler

Piper Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $15 from $13 and keeps an...

11d ago

ADPT

Adaptive Biotechnologies price target raised to $15 from $13 at TD Cowen

TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $15 from $13 and keeps a...

11d ago

ADPT

Adaptive Biotechnologies price target raised to $14 from $10 at JPMorgan

JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $14 from $10 and...

11d ago

ADPT

Adaptive Biotechnologies reports Q2 EPS (17c), consensus (24c)

Reports Q2 revenue $58.88M, consensus $49.4M. “We delivered an outstanding second quarter, achieving profitability in our MRD business...

11d ago

ADPT

COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made aggressive moves in the crypto space on August 1, snapping...

13d ago

ADPT

BMNR

Cathie Wood Buys $69M Worth of Figma Stock on Blockbuster IPO Debut

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) snapped up 60,000 shares of newly-listed tech company Figma ($FIG) on July 31....

15d ago

AMD

Adaptive Biotechnologies price target raised to $13 from $11 at BTIG

BTIG raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $13 from $11 and keeps a Buy...

19d ago

ADPT

Adaptive Biotechnologies’ Earnings Call Highlights Growth

Adaptive Biotechnologies (($ADPT)) has held its Q2 earnings call. Read on for the main highlights of the call....

10d ago

ADPT

Strong Financial Performance and Growth Potential Drive Buy Rating for Adaptive Biotechnologies

William Blair analyst Andrew Brackmann has reiterated their bullish stance on ADPT stock, giving a Buy rating today....

11d ago

ADPT

Adaptive Biotechnologies Reports Strong Q2 2025 Growth

Adaptive Biotechnologies ( ($ADPT) ) has released its Q2 earnings. Here is a breakdown of the information Adaptive...

11d ago

ADPT

Adaptive Biotechnologies: Strong Financial Performance and Strategic Initiatives Drive Optimistic Outlook

In a report released yesterday, Daniel Brennan from TD Cowen reiterated a Buy rating on Adaptive Biotechnologies, with...

11d ago

ADPT

Adaptive, Flatiron Health integrates clonoSEQ MRD testing into OncoEMR

Adaptive Biotechnologies (ADPT) and Flatiron Health announced the integration of Adaptive’s clonoSEQ test for measurable residual disease, MRD,...

2M ago

ADPT

Craig-Hallum bullish on Adaptive Biotechnologies, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $15 price target....

2M ago

NEO

ADPT

Adaptive Biotechnologies initiated with a Buy at Craig-Hallum

Craig-Hallum analyst John Wilkin initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $15 price target...

2M ago

ADPT

ADPT FAQ

What was Adaptive Biotechnologies Corp’s price range in the past 12 months?

Adaptive Biotechnologies Corp lowest stock price was $3.98 and its highest was $13.37 in the past 12 months.

What is Adaptive Biotechnologies Corp’s market cap?

Adaptive Biotechnologies Corp’s market cap is $1.97B.

When is Adaptive Biotechnologies Corp’s upcoming earnings report date?

Adaptive Biotechnologies Corp’s upcoming earnings report date is Oct 30, 2025 which is in 74 days.

How were Adaptive Biotechnologies Corp’s earnings last quarter?

Adaptive Biotechnologies Corp released its earnings results on Aug 05, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.239 by $0.069.

Is Adaptive Biotechnologies Corp overvalued?

According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adaptive Biotechnologies Corp pay dividends?

Adaptive Biotechnologies Corp does not currently pay dividends.

What is Adaptive Biotechnologies Corp’s EPS estimate?

Adaptive Biotechnologies Corp’s EPS estimate is -0.2.

How many shares outstanding does Adaptive Biotechnologies Corp have?

Adaptive Biotechnologies Corp has 152,273,910 shares outstanding.

What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?

Adaptive Biotechnologies Corp reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.239. Following the earnings report the stock price went up 5.792%.

Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?

Currently, no hedge funds are holding shares in ADPT

Adaptive Biotechnologies Stock Smart Score

Outperform

Fundamentals

Return on Equity

-57.55%

Trailing 12-Months

Asset Growth

-15.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) is a biotechnology company specializing in the development of innovative genomic technologies to improve the diagnosis and treatment of diseases, particularly in the fields of oncology and immunology. The company focuses on harnessing the power of the adaptive immune system to create advanced tools for disease detection, monitoring, and therapeutic development. Its core products include its clonoSEQ platform for measuring minimal residual disease in blood cancers and immune profiling services that help in understanding immune responses to various diseases.

Adaptive Biotechnologies (ADPT) Earnings & Revenues

Historic Earnings Reports

ADPT Company Deck

ADPT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a robust performance with strong revenue growth, successful profitability in the MRD business, and improved financial metrics. While there are dependencies on milestone payments and future collaborations for continued growth, the positive aspects significantly outweigh the challenges.View all ADPT earnings summaries

ADPT Stock 12 Month Forecast

Average Price Target

$13.75

▲(5.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","16":"$16","6.25":"$6.25","9.5":"$9.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.25,9.5,12.75,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,10.68923076923077,11.048461538461538,11.407692307692308,11.766923076923078,12.126153846153846,12.485384615384616,12.844615384615384,13.203846153846154,13.563076923076924,13.922307692307692,14.281538461538462,14.64076923076923,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,10.593076923076923,10.856153846153846,11.11923076923077,11.382307692307693,11.645384615384616,11.90846153846154,12.17153846153846,12.434615384615384,12.697692307692307,12.96076923076923,13.223846153846154,13.486923076923077,{"y":13.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.33,10.381538461538462,10.433076923076923,10.484615384615385,10.536153846153846,10.587692307692308,10.63923076923077,10.69076923076923,10.742307692307692,10.793846153846154,10.845384615384615,10.896923076923077,10.948461538461538,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >